Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants

PURPOSE: BMS-986142 is an oral, small-molecule reversible inhibitor of Bruton’s tyrosine kinase. The main objectives of our phase I studies were to characterize the safety and tolerability, pharmacokinetics, and pharmacodynamics of BMS-986142 in healthy participants, and to investigate the potential...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Clin Pharmacol
Main Authors: Lee, Sun Ku, Xing, Jun, Catlett, Ian M., Adamczyk, Robert, Griffies, Amber, Liu, Ang, Murthy, Bindu, Nowak, Miroslawa
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2017
Assuntos:
Clinical Trial
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5423977/
https://ncbi.nlm.nih.gov/pubmed/28265691
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00228-017-2226-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados